Search results

Page results

• Repurposed drug improves outcomes for patients with severe COVID-19 pneumonia

  A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.

• IR Non-Tunnelled CVC Line Insertion (Vascath)

  This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.

• IR PICC (Peripherally Inserted Central Catheter) Insertion

  This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Interventional Radiology team.

• IR Vortex® Port-a-cath Insertion

  This booklet tells you about having a Vortex® Port-a-cath Insertion (implantable port) with the Interventional Radiology team.

• VA PICC (Peripherally Inserted Central Catheter) Insertion

  This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Vascular Access team.

• National dementia research role for UCLH clinician

  UCLH consultant neurologist Dr Catherine Mummery has been announced as the new Chair of the NIHR Dementia Translational Research Collaboration.

• Faster diagnosis pathway for gynaecology

  This page is for patients who have been referred by their GP to a gynaecology specialist because their symptoms need further tests.

• UCLH to be part of vital health data partnership

  UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.

• UCLH researchers find way to reduce side effects of treatment for adrenal disorder

  A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.

• History making decision announced for Thalassaemia patients!

  Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.